期刊文献+

类风湿关节炎患者血清中组织蛋白酶S的表达及与DAS-28的相关性 被引量:4

Correlation between serum cathepsin S and DAS-28 in the rheumatoid arthritis patients
暂未订购
导出
摘要 目的研究类风湿关节炎(RA)患者血清中组织蛋白酶S(Cat S)的表达情况及与DAS-28的关系。方法选取64例RA患者,评估其疾病活动度(DAS28-ESR和DAS28-CRP),检测其外周血中CatS和Ⅱ型胶原表达的变化情况,同时收集64例健康体检者作为对照组,应用GraphPad Prism5.01软件进行统计分析。结果与对照组比较,RA患者血清中CatS显著升高[(53.68±25.71)ng/ml比(3.09±1.83)ng/ml,P〈0.01],且与DAS28-ESR、DAS28-CRP和类风湿因子(RF)呈正相关,而与抗环瓜氨酸肽(CCP)抗体间无关。而Ⅱ型胶原的表达与DAS28-ESR、DAS28-CRP、RF和抗CCP抗体间均无相关,但CatS与Ⅱ型胶原间呈负相关(r=-0.381,P〈0.05)。结论CatS可能参与RA的发病过程,其表达变化与疾病活动度相关。 Objective To investigate the correlation of serum Cat S and disease activity score (DAS)-28 in the rheumatoid arthritis (RA) patients. Mehods 64 patients of rheumatoid arthritis were enrolled. The disease activity, DAS 28-ESR and DAS 28-CRP were evaluated. The expression of Cat S and collagen Ⅱ in serum were detected. Statistical analysis by GraphPad Prism 5.01. Results The expression Cat S of in the serum was much higher than that of the control [ (53.68 ± 25.71 ) ng/ml vs ( 3.09 ± 1.83 ) ng/ml,P 〈0.01 ]. The level of Cat S was linear correlated with the disease activity of rheumatoid arthritis and the level of rheumatoid factor, but was not correlated with the level of anti-CCP. On the contrary, the level of collagen Ⅱ was not correlated with the disease activity of rheumatoid arthritis, the level of rheuma- toid factor or the level of anti-CCP,but was negative correlated with the level of Cat S( r = -0. 381 ,P 〈 0.05). Conclusion Cat S should be involved in the pathogenesis of rheumatoid arthritis and the expres- sion in serum of RA patients was correlated with the disease activity.
出处 《临床内科杂志》 CAS 2015年第10期680-682,共3页 Journal of Clinical Internal Medicine
基金 国家自然科学基金面上项目(30972747、81172875)
关键词 组织蛋白酶S 类风湿关节炎 疾病活动度 Cathepsin S Rheumatoid arthritis Disease activity
  • 相关文献

参考文献9

  • 1Shi GP, Webb AC, Foster KE, et al. Human cathepsin S : chromosomal localization, gene structure, and tissue distribution [ J ]. J Biol Chem, 1994,269 ( 15 ) : 11530-11536.
  • 2Shi GP, Vinadangos JA, Dranoff G, et al. Cathepsin S required for nor- mal MHC class II peptide loading and germinal center development [ J ]. Immunity, 1999,10 (2) : 197-206.
  • 3Perisic NM, Sabotie J ,Jewett A, et al. Cysteine eathepsins as regulators of the cytotoxieity of NK and T cells[ J]. Front Immunol,2014 ,5 :616.
  • 4Hou WS, Li Z, Buttner FH, et al. Cleavage site specificity of eathepsin K toward cartilage proteoglyeans and protease complex formation [J]. Biol Chem,2003,384(6) :891-897.
  • 5Hou WS, Li W, Keyszer G, et al. Comparison of cathepsins K and S ex- pression within the rheumatoid and osteoarthritic synovium [J]. Arthritis Rheum,2002,46 ( 3 ) : 663 -674.
  • 6Nakagawa TY, Brissette WH, Lira PD, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in eathepsin S null mice [ J ]. Immunity, 1999, 10 ( 2 ) : 207 -217.
  • 7Pozgan U, Caglie D, Rozman B, et al. Expression and activity profiling of selected cysteine eathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis [ J ]. Biol Chem,2010,391 (5) :571-579.
  • 8Baugh M, Black D, Westwood P, et ah Therapeutic dosing of an orally active,selective eathepsin S inhibitor suppresses disease in models of autoimmunity [ J ]. J Autoimmun, 2011,36 ( 3-4 ) : 201-209.
  • 9Clark AK, Yip PK, Malcangio M. The liberation of fractalkine in the dorsal horn requires microglial cathepsin S [ J ]. J Neuresci, 2009,29 (21) :6945-6954.

同被引文献45

  • 1Vitali C,Bombardieri S,Jonsson R,et al.Classification criteria for Sjogren’s syndrome:a revised version of the European criteria proposed by the American-European Consensus Group[J].Ann Rheum Dis,2002,61:554-558.
  • 2Shiboski SC,Shiboski CH,Criswell L,et al.American College of Rheumatology classification criteria for Sjogren’s syndrome:a data-driven,expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort[J].Arthritis Care Res(Hoboken),2012,64:475-487.
  • 3Seror R,Ravaud P,Bowman SJ,et al.EULAR Sjogren’s syndrome disease activity index:development of a consensus systemic disease activity index for primary Sjogren’s syndrome[J].Ann Rheum Dis,2010,69:1103-1109.
  • 4Maslinska M,Przygodzka M,Kwiatkowska B,et al.Sjogren’s syndrome:still not fully understood disease[J].Rheumatol Int,2015,35:233-241.
  • 5Roche PA,Furuta K.The ins and outs of MHC classⅡ-mediated antigen processing and presentation[J].Nat Rev Immunol,2015,15:203-216.
  • 6Gupta S,Singh RK,Dastidar S,et al.Cysteine cathepsin S as an immunomodulatory target:present and future trends[J].Expert Opin Ther Targets,2008,12:291-299.
  • 7Wang B,Sun J,Kitamoto S,et al.Cathepsin S controls angiogenesis and tumor growth via matrixderived angiogenic factors[J].J Biol Chem,2006,281:6020-6029.
  • 8Saegusa K,Ishimaru N,Yanagi K,et al.Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity[J].J Clin Invest,2002,110:361-369.
  • 9Li X,Wu K,Edman M,et al.Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse[J].Invest Ophthalmol Vis Sci,2010,51:5019-5029.
  • 10Lee-Dutra A,Wiener DK,Sun S.Cathepsin S inhibitors:2004-2010[J].Expert Opin Ther Pat,2011,21:311-337.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部